These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38520149)

  • 1. Sodium-glucose cotransporter-2 inhibitors and the risk of atrial fibrillation in patients with type 2 diabetes: a population-based cohort study.
    Eroglu TE; Coronel R; Souverein PC
    Eur Heart J Cardiovasc Pharmacother; 2024 Jul; 10(4):289-295. PubMed ID: 38520149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of sodium-glucose cotransporter-2 inhibitors and the risk for sudden cardiac arrest and for all-cause death in patients with type 2 diabetes mellitus.
    Eroglu TE; Coronel R; Zuurbier CJ; Blom M; de Boer A; Souverein PC
    Eur Heart J Cardiovasc Pharmacother; 2022 Dec; 9(1):18-25. PubMed ID: 35894858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident Atrial Fibrillation in Older Adults With Type 2 Diabetes.
    Zhuo M; D'Andrea E; Paik JM; Wexler DJ; Everett BM; Glynn RJ; Kim SC; Patorno E
    JAMA Netw Open; 2022 Oct; 5(10):e2235995. PubMed ID: 36219443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prescribing sodium-glucose co-transporter-2 inhibitors for type 2 diabetes in primary care: influence of renal function and heart failure diagnosis.
    Hinton W; Feher MD; Munro N; Joy M; de Lusignan S
    Cardiovasc Diabetol; 2021 Jun; 20(1):130. PubMed ID: 34183018
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SGLT2 inhibitors and atrial fibrillation in type 2 diabetes: a systematic review with meta-analysis of 16 randomized controlled trials.
    Li WJ; Chen XQ; Xu LL; Li YQ; Luo BH
    Cardiovasc Diabetol; 2020 Aug; 19(1):130. PubMed ID: 32847602
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sex Differences in Cardiovascular Effectiveness of Newer Glucose-Lowering Drugs Added to Metformin in Type 2 Diabetes Mellitus.
    Raparelli V; Elharram M; Moura CS; Abrahamowicz M; Bernatsky S; Behlouli H; Pilote L
    J Am Heart Assoc; 2020 Jan; 9(1):e012940. PubMed ID: 31902326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular Outcomes Among Patients with Type 2 Diabetes Newly Initiated on Sodium-Glucose Cotransporter-2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists, and Other Antidiabetic Medications.
    Pineda ED; Liao IC; Godley PJ; Michel JB; Rascati KL
    J Manag Care Spec Pharm; 2020 May; 26(5):610-618. PubMed ID: 32347181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose Cotransporter-2 Inhibitors).
    Kosiborod M; Cavender MA; Fu AZ; Wilding JP; Khunti K; Holl RW; Norhammar A; Birkeland KI; Jørgensen ME; Thuresson M; Arya N; Bodegård J; Hammar N; Fenici P;
    Circulation; 2017 Jul; 136(3):249-259. PubMed ID: 28522450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of combination treatment with glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on incidence of cardiovascular and serious renal events: population based cohort study.
    Simms-Williams N; Treves N; Yin H; Lu S; Yu O; Pradhan R; Renoux C; Suissa S; Azoulay L
    BMJ; 2024 Apr; 385():e078242. PubMed ID: 38663919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review.
    Rao S
    Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG; Han SJ; Kim DJ; Lee KW; Kim HJ
    Cardiovasc Diabetol; 2018 Jun; 17(1):91. PubMed ID: 29935543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of weight loss related to risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium-glucose cotransporter 2 inhibitor.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Cardiovasc Diabetol; 2021 Apr; 20(1):93. PubMed ID: 33941171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
    Jang J; Park S; Kim S; Kim SH; Oh YS; Sa YK; Hwang Y; Jang SW; Ihm SH; Choi Y
    Eur J Prev Cardiol; 2024 Feb; 31(3):320-329. PubMed ID: 37798123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors.
    Ling AW; Chan CC; Chen SW; Kao YW; Huang CY; Chan YH; Chu PH
    Cardiovasc Diabetol; 2020 Nov; 19(1):188. PubMed ID: 33158436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between sodium-glucose cotransporter-2 inhibitors and arrhythmic outcomes in patients with diabetes and pre-existing atrial fibrillation.
    Fichadiya A; Quinn A; Au F; Campbell D; Lau D; Ronksley P; Beall R; Campbell DJT; Wilton SB; Chew DS
    Europace; 2024 Mar; 26(3):. PubMed ID: 38484180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sodium-glucose cotransporter-2 inhibitors compared with glucagon-like-peptide-1 receptor agonists and out-of-hospital cardiac arrest in type 2 diabetes: a nationwide nested case-control study.
    Júlíusdóttir YK; Halili A; Coronel R; Folke F; Torp-Pedersen C; Gislason GH; Eroglu TE
    Eur Heart J Cardiovasc Pharmacother; 2023 Jul; 9(5):437-443. PubMed ID: 37173284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SGLT-2 inhibitors and atrial fibrillation in the Food and Drug Administration adverse event reporting system.
    Bonora BM; Raschi E; Avogaro A; Fadini GP
    Cardiovasc Diabetol; 2021 Feb; 20(1):39. PubMed ID: 33573667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renoprotective effect of SGLT-2 inhibitors among type 2 diabetes patients with different baseline kidney function: a multi-center study.
    Lin FJ; Wang CC; Hsu CN; Yang CY; Wang CY; Ou HT
    Cardiovasc Diabetol; 2021 Oct; 20(1):203. PubMed ID: 34620182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
    Grabner M; Peng X; Geremakis C; Bae J
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial.
    Zelniker TA; Bonaca MP; Furtado RHM; Mosenzon O; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Budaj A; Kiss RG; Padilla F; Gause-Nilsson I; Langkilde AM; Raz I; Sabatine MS; Wiviott SD
    Circulation; 2020 Apr; 141(15):1227-1234. PubMed ID: 31983236
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.